Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT

NCT07166445 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07166445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07166445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2024
Completion date
December 1, 2027
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, deep learning, diagnostic imaging, pathology